Spine Osteoarthritis

A degenerative joint disease involving the SPINE. It is characterized by progressive deterioration of the spinal articular cartilage (CARTILAGE, ARTICULAR), usually with hardening of the subchondral bone and outgrowth of bone spurs (OSTEOPHYTE).

Also Known As:

Networked: 23 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Osteoporosis
2.	Osteoarthritis
3.	Low Back Pain (Lumbago)
4.	Pain (Aches)
5.	Tendinopathy (Tendonitis)

Experts

1.	Cooper, Cyrus: 2 articles (02/2012 - 04/2005)
2.	Reginster, Jean-Yves: 2 articles (02/2012 - 12/2008)
3.	Usui, Takahiko: 2 articles (01/2007 - 01/2007)
4.	Sasaki, Noriko: 2 articles (01/2007 - 01/2007)
5.	Hosoi, Takayuki: 2 articles (01/2007 - 01/2007)
6.	Nakamura, Toshitaka: 2 articles (01/2007 - 01/2007)
7.	Narusawa, Ken'ichiro: 2 articles (01/2007 - 01/2007)
8.	Urano, Tomohiko: 2 articles (01/2007 - 01/2007)
9.	Inoue, Satoshi: 2 articles (01/2007 - 01/2007)
10.	Ouchi, Yasuyoshi: 2 articles (01/2007 - 01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Spine Osteoarthritis:

1.	Piroxicam (Feldene)FDA LinkGeneric 01/01/2009 - "The piroxicam patch is effective in the treatment of lumbar osteoarthritis and has demonstrated to be well tolerated and it improves patients compliance. " 01/01/2009 - "The piroxicam patch offers a comparable alternative to the marketed piroxicam cream for the treatment of lumbar osteoarthritis with the advantage of a better compliance with the once a day application of the patch compared to three daily applications for the piroxicam cream." 01/01/2009 - "In order to assess the efficacy and safety of a new patch containing 14 mg of piroxicam (CAS 36322-90-4) 1%, applied once daily, in comparison with a reference marketed formulation, piroxicam 1% cream applied three times a day, placebo patch applied once daily, a randomized, placebo-controlled, parallel-group clinical trial was carried out by general practitioners in patients with lumbar osteoarthritis aged between 18 and 75 years. " 01/01/2009 - "Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis. " 10/01/1990 - "A clinical trial comparing a new NSAID (droxicam) and piroxicam in spinal osteoarthritis."
2.	strontium ranelate (protelos)IBA 03/01/2008 - "The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA). " 12/01/2008 - "Preliminary results suggest that strontium ranelate is able to reduce the progression of spine osteoarthritis. " 03/01/2008 - "Effects of strontium ranelate on spinal osteoarthritis progression." 02/01/2012 - "Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom- and structure-modifying activity in osteoarthritis. "
3.	Biological Markers (Surrogate Marker)IBA 01/01/2010 - "Imaging biomarkers of spine osteoarthritis." 02/01/2012 - "Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom- and structure-modifying activity in osteoarthritis. "
4.	Carbon MonoxideIBA 11/01/2011 - "This study uses data from the 14,507 participants of the European Health Interview Survey conducted in Austria in 2006/2007 to calculate estimates of the prevalence of osteoarthritis, spinal conditions, and osteoporosis in a population representative of other European Union or Organisation for Economic Co-operation and Development member states. "
5.	Glucosamine (Dona)IBA 07/01/1997 - "Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment." 01/01/2013 - "To ascertain whether the use of oral glucosamine influences symptoms or functional outcomes in patients with chronic low back pain (LBP) thought to be related to spinal osteoarthritis (OA). " 07/07/2010 - "Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial." 03/01/2011 - "To systematically search and assess the quality of the literature on the use of glucosamine, chondroitin sulfate, and methylsulfonylmethane for the treatment of spinal osteoarthritis / degenerative joint disease, and degenerative disc disease. "
6.	CalciumIBA 04/01/1991 - "Altogether 58 women were excluded from the final analysis due to significant spinal osteoarthritis or other diseases or drugs known to influence calcium or bone metabolism. " 10/01/2008 - "Among 249 women consulting for either shoulder tendonitis or lumbar spine osteoarthritis, 121 free of conditions and drugs affecting bone and calcium metabolism completed two food-frequency questionnaires within 15 d and we selected the 85 subjects with retest scores within the +/- 15% of test scores. "
7.	beta CateninIBA 01/01/2007 - "Thus, we suggest that a genetic variation in the WISP1 gene locus is associated with spinal osteoarthritis, in line with the involvement of the Wnt-beta-catenin-regulated gene in bone and cartilage metabolism."
8.	LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)IBA 01/01/2007 - "To determine the association of single-nucleotide polymorphism (SNP) causing an amino-acid change (Q89R) in the low-density lipoprotein receptor-related protein 5 (LRP5) coding region with spinal osteoarthritis. " 01/01/2007 - "Q89R polymorphism in the LDL receptor-related protein 5 gene is associated with spinal osteoarthritis in postmenopausal Japanese women."
9.	Calcitriol Receptors (Calcitriol Receptor)IBA 04/01/2005 - "To investigate risk factors for adult lumbar spine osteoarthritis (OA) including polymorphisms of the vitamin D receptor gene (VDR) and birthweight. " 04/01/2005 - "Birthweight, vitamin D receptor gene polymorphism, and risk of lumbar spine osteoarthritis."
10.	Vitamin DFDA LinkGeneric 07/31/2000 - "We have shown that a T(869)-->C polymorphism of the transforming growth factor-beta1 (TGF-beta1) gene, which results in a Leu-->Pro substitution at amino acid 10, is associated with bone mineral density in Japanese adolescents and postmenopausal women, with genetic susceptibility to osteoporosis or spinal osteoarthritis, and with the outcome of treatment for osteoporosis with active vitamin D. "

Therapies and Procedures

1.	Ambulatory Care (Outpatient Care) 07/01/2006 - "We examined the association of spine osteoarthritis and bone mineral density in 1082 community-dwelling ambulatory older women aged 50-96 years who participated in a 1992-1996 osteoporosis research clinic visit. "
2.	Activities of Daily Living (ADL) 10/01/1996 - "Ther., 13 (1982) 363-375), that required subjects to sit, stand, walk, and recline for 1-2 minute periods (which we have labelled the traditional protocol), and a second, more demanding protocol that was designed to simulate activities of daily living that place a premium on axial movement (the 'ADL' protocol); (3) disability was assessed using the Roland questionnaire, a 6 month global disability question and the Jette Functional Status Index; and (4) radiographic evaluation of the lumbosacral spine; osteoarthritis was quantitated using a previously validated scoring system. "